VeraDermics (NYS: MANE) key facts
- Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions.
- VeraDermics (NYS: MANE)’s last known valuation is $596.3M (Feb 2026).
- It has raised $518.6M across 1 recorded rounds; the latest was Later Stage VC (Series C) ($150.0M) in Oct 2025.
- Notable investors include Viking Global Investors, Connecticut Innovations, The Invus Group, Osage University Partners, Marshall Wace — 26 tracked in total.
- 4 institutional filers report fund marks on VeraDermics (NYS: MANE) across 9 filings.
- Status: Publicly Held.
Who backs VeraDermics (NYS: MANE)
26+- ·The complete investor list: 26 names
- ·Watch VeraDermics (NYS: MANE): the Monday email on marks, rounds and moves
VeraDermics (NYS: MANE) funding rounds
1 roundsVeraDermics (NYS: MANE) valuation
VeraDermics (NYS: MANE) is now publicly traded; this page covers its private-market history, where its last recorded valuation was $596 million (Feb 2026). Secondary trades, fund marks and rounds below are the private-market record; the listed share price is not tracked here.
Recent activity
In the last 90 days, VeraDermics (NYS: MANE)'s record added 1 institutional fund mark (latest period Jul 2026).
How much has VeraDermics (NYS: MANE) raised?
VeraDermics (NYS: MANE) has raised $519 million in total; 1 of its rounds is on record. The largest on record was a $150 million Series C in Oct 2025.
Institutional holders and vehicles
4 SEC-registered funds reported 9 fair-value marks on VeraDermics (NYS: MANE) between Feb 2026 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.
VeraDermics (NYS: MANE) investors
26 investors are on record for VeraDermics (NYS: MANE), including Viking Global Investors, Connecticut Innovations, The Invus Group and Osage University Partners. By type, the record holds 3 venture capital firms, 3 hedge funds and 2 asset managers. The Series C in Oct 2025 drew 10 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Superluminal Medicines ($576 million), Strand Therapeutics ($571 million) and Bambusa Therapeutics ($555 million).
About VeraDermics (NYS: MANE)
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- New Haven, CT, United States
- Founded
- 2019
- Employees
- 19
- Website
- veradermics.com/
- Ownership
- Publicly Held
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
VeraDermics (NYS: MANE)’s last known valuation, Feb 2026. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.
Institutional fund marks on VeraDermics (NYS: MANE)
4 filers · latest Jul 20264 SEC-registered funds reported 9 fair-value marks on VeraDermics (NYS: MANE) between Feb 2026 and Jul 2026. Filer-level marks and implied $/share are available to Pro members.
Membership and data by Private Market View